NCT02201550

Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide

Regulation of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide (Victoza)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 9 (actual)
• Sponsor: Hvidovre University Hospital · Academic / Other
• Sex: Male
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effect of exogenous glucagon-like peptide-1 on the immune system i.e on the regulation of immune cells important in diseases such as obesity and diabetes. The hypotheses are: * Glucagon-like peptide-1 has an immunological effect observed by studying immune cells in the blood * Treatment with glucagon-like peptide-1 increases the number of immune cells in the blood * Treatment with glucagon-like peptide-1 leads to a more anti-inflammatory cytokine profile in the blood

Conditions

• Type 2 Diabetes Mellitus

Timeline

• Start date: 2013-02-01
• Primary completion: 2014-04-01
• Completion: 2014-04-01
• First posted: 2014-07-28
• Last updated: 2014-07-28

Locations

1 site across 1 country: Denmark